20.5 C
New York
Thursday, June 18, 2026

Tag: prescription

newssourceFORcompanyinformationcontent1marketreleases

SAFILO GROUP AND VICTORIA BECKHAM ANNOUNCE A TEN-YEAR GLOBAL LICENSING AGREEMENT FOR EYEWEAR COLLECTIONS

PADUA, Italy and LONDON, July 1, 2025 /PRNewswire/ -- Safilo Group – one of the eyewear industry's key players in the design, manufacturing and distribution...

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses. July 22, 2025 Deadline to file Lead Plaintiff Motion

Investors can contact the law firm at no cost to learn more about recovering their losses

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio

BleeqUp Showcases Revolutionary AI Cycling Glasses at Eurobike 2025

FRANKFURT, Germany, June 30, 2025 /PRNewswire/ -- BleeqUp, an AI-powered outdoor sports technology brand, showcased its groundbreaking BleeqUp Ranger at Eurobike 2025. Hailed as...

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead the Sarepta...

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta’s top executives with violations of the Securities Exchange Act of 1934.

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

CCHR Calls for Immediate Ban on Electroshock Treatment Across Europe

Citizens Commission on Human Rights (CCHR) groups from across Europe protested in Madrid during the 33rd European Congress of Psychiatry, demanding an end to coercive...

INVESTOR DEADLINE: Robbins Geller Announces that Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon as well as certain of Organon’s top executives with violations of the Securities Exchange Act of 1934.

Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million

Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses, today shares its financial results for the year ended March 31, 2025.

Chronic Conditions Surge in U.S. Workforce While Disability Claims Decline, Signaling a New Workforce Health Paradox

OAKLAND, Calif., June 26, 2025 /PRNewswire/ -- More than 78% percent of employees in the US now have at least one chronic condition, an...

HIMS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead...

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.).

Craft Telemedicine Launches to Redefine Specialty Care with Human-Centered Platform

Revolutionary no-subscription telemedicine model gives patients complete control over specialized compounded medications and pharmacy choice. TULSA, Okla., June 25, 2025 /PRNewswire/ -- Craft Telemedicine today...

Glokore Light Therapy Mask Earns Spotlight as Non-Invasive Red Light Skincare Solution Backed by User Satisfaction

LED-Based Skincare Device Highlighted for Non-Invasive Anti-Aging and Acne Support Backed by Clinical Usage Data 
LED-Based Skincare Device Highlighted for Non-Invasive Anti-Aging and Acne Support Backed by Clinical Usage Data

Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.

PHILADELPHIA, June 24, 2025 /PRNewswire/ -- Berger Montague, a nationally recognized securities litigation firm, is investigating potential claims on behalf of investors who purchased or...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrescription

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers